Старение. Профессиональный врачебный подход

   98. Ingram D.C., Nakamura K., Smucny D. Strategy for identifying biomarkers of aging in long-lived species // Exp. Cerontol. 2001. Vol. 36. P. 1025–1034.

   99. Jak ovljevic M., Reiner Z., Milicic D., Crncevic Z. Comorbidity, multimorbidity and personalized psychosomatic medicine: epigenetics rolling on the horizon. Psychiatr Danub. 2010 Jun;22(2):184-9.

   100. Jazwinski S.M. Genetics of longevity. Exp. Gerontol. 1998. Vol. 33. P. 773–783.

   101. Jensen I. Proceedings: Pathology and prognostic factors in temporal lobe epilepsy. Follow-up after temporal lobe resection // Acta Neurochir, 1975; 31(3–4): 261-2.

   102. Jialal I., Devaraj S. Antioxidants and atherosclerosis. Don’t throw out the baby with the bath water. Circulation. 2003. Vol. 107. P. 926–928.

   103. Jlrich P., Ceratni A. Protein glycation, diabetes, and aging // Recent Progr. Horm. Res. 2001. Vol. 56. P. 1–21.

   104. Kaplan M.H., Feinstein A.R. The importance of classifying initial comorbidity in evaluating the outcome of diabetes mellitus // Journal Chronic Disease, 1974; 27: 387–404, 1 974

   105. Kaplan M.H., Feinstein A.R. Acritique of methods in reported studies of long-term vascular complications in patients with diabetes mellitus // Diabetes, 1973; 22(3): 160-174

   106. Kipling D., Faragfter R. G. A. Ageing hard or hardly ageing? Nature. 1999. Vol, 398. P. 191–192.

   107. Kirk D. Demographic transition theory. Popul. Stud. 1996. Vol. 50. P. 361–387.

   108. Kirkwood T.B.L Evolution of ageing. Mech. Ageing Dev. 2002. Vol. 123. p. 737–745.

   109. Kishi S., Uchiyama J., Baughman A.M. et al. The zebrafish as a vertebrate model of functional aging and very gradual senescence // Exp. Getontol. 2003. Vol. 38. P. 777–786.

   110. Konhilas J.P., Leinwand L.A. Partnering up for cardiac hypertrophy // Circ Res 2006; 98 (8): 985–987 and Comment Circ Res 2006; 98 (8): 1089–1097.

   111. Korpelaii K. Human life histories and the demographic transition: A case study from Finland, 1870–1949. Am. J. Phys. Anthropol. 2003. Vol. 120. P. 384–390.

   112. Kowald A. Lifespan does not measure ageing // Biogerontology. 2001. Vol. 3. P. 187–190.

   113. Kraemer H.C. Statistical issues in assessing comorbidity // Stat Med, 1995; 14:721–723

   114. Krishnan E. Hyperuricemia and Incident Heart Failure // Circ Heart Fail 2009; 2: 556–62.

   115. Kruseman A.C., Mulder W.J., Pijpers E. Ageing and polymorbidity: is there a mismatch between the training of internists and the need? Neth J Med. 2007 Nov;65(10):363-5.

   116. Laine H., Katoh C., Luotolahti M. Myocardial oxygen consumption is unchanged but efficiency is reduced in patients with essential hypertension and left ventricular hypertrophy // Circulation 1999; 100: 2425-30.

   117. Lango R., Smolenski R.T., Narkiewicz M. Influence of L-carnitine and its derivatives on myocardial metabolism and function in ischemic heart disease and during cardiopulmonary bypass // Cardiovasc. Res. 2001. Vol. 51, № 1. P. 21–29.

   118. Lee C.K., Klopp R.C, Weindruch R., Prolla T.A. Gene expression profile of aging and its retardation by caloric restriction // Science. 1999. Vol. 285. P. 1390–1393.

   119. Lee L., Horowitz J., Frenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment // Eur. Heart J. 2004. Vol. 25, № 8. P. 634–641.

   120 . Lee S.J., Lindquist K., Segal M.R., Covinsky K.E. Development and validation of a prognostic index for 4-year mortality in older adults // JAMA, 2006; Feb;15;295:801-8.

   121. Linn B.S., Linn M.W., Gurel L. Cumulative illness rating scale. J Amer Geriatr Soc // 1968; 16:622–626.

   122. Lio D., Mario Pes C., Carru С. et al. Association between the HLA DR alkies and longevity: a study in Sardinian population //Exp. Gerontol. 2003. Vol. 38. P. 313–318.

   123. Littdenberger U., Sikstrvm S. Aging cognition: from neuromodulation to representation Trends Cogn. Sci. 2001. Vol. 5. P. 479–486.

   124. Lopaschuk G.D., Wall S.R., Olley P.M. Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chainacylcarnitine // Circ. Res. 1988. Vol. 63. № 6. P. 1036–1043.

   125. Lovell M. Caring for the elderly: Changing pe rceptions and attitudes. J. Vasc. Nurs. 2006. Vol. 24(1). Р. 22–26.

   126. Makeham W. M. On the Law of Mortality, and Construction of Annuity Tables. JIA, VIII. 1860.

   127. Makolkin V., Osadchiy K. Trimetazidine modified release in the treatment of stable angina. TRIUMPH Study // Clin. Drug Invest. 2004. Vol. 24, № 12. – P. 731–738.

   128. Marengoni A., Angleman S., Melis R., Mangialasche F., Karp A., Garmen A., Meinow B., Fratiglioni L. Aging with multimorbidity: A systematic review of the literature.

   129. Marian A. J. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy // Lancet, 2000. V. 355. P. 58–60.

   130. Martínez Velilla N. Multimorbidity: the ultimate geriatric syndrome. Rev Esp Geriatr Gerontol. 2010 Jul-Aug;45(4): 177-8. Epub 2010 May 12.